S-1/A: Applied UV Files Amendment No. 1 to Form S-1 for Resale of 518,065 Common Shares

Applied UV, Inc. has filed an amendment to its Form S-1 registration statement to allow selling stockholders to offer and resell up to 518,065 shares of common stock issuable upon exercise of warrants.

Summary

• Applied UV, Inc. (AUVI) has filed Amendment No. 1 to its Form S-1 registration statement with the SEC.
• This amendment primarily incorporates by reference SEC filings omitted from or filed after the original filing on April 16, 2024.
• The prospectus relates to the offering and resale of up to 518,065 shares of common stock (Warrant Shares) by selling stockholders.
• These shares are issuable upon the exercise of warrants issued in a private placement on April 1, 2024.
• Applied UV will not receive any proceeds from the sale of these shares by the selling stockholders.
• If all warrants were exercised for cash, AUVI would receive approximately $8.3 million, which it intends to use for general corporate purposes, including working capital.
• AUVI's common stock is listed on The Nasdaq Capital Market under the symbol AUVI.
• As of April 22, 2024, the closing price of AUVI's common stock was $0.59.
• The company is an emerging growth company and a smaller reporting company, allowing it to take advantage of certain reduced public company reporting requirements.
• As of April 23, 2024, AUVI had 131 employees.

Sentiment

Score: 5

Explanation: The document is neutral. It primarily describes the offering and resale of common stock by selling stockholders. While the potential influx of cash from warrant exercises is positive, the company's low stock price and potential for dilution are concerning.

Positives

• Potential influx of $8.3 million if all warrants are exercised for cash, which would be used for general corporate purposes and working capital.
• The company can leverage Canon Virginia, Inc.'s (CVI) extensive field support team to promote the sale of its products and service capabilities.
• The company has a global network of 89 dealers and distributors in 52 countries, 47 manufacturing representatives, and 19 U.S.-based internal sales representatives.

Negatives

• The company will not receive any proceeds from the sale of common stock by the selling stockholders.
• The trading price of the company's common stock has been and may continue to be subject to wide price fluctuations.
• The company's stock price closed at $0.59 on April 22, 2024, indicating a low valuation.
• The company is dependent on the selling stockholders exercising their warrants.

Risks

• Investing in the company's common stock involves a high degree of risk.
• The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to existing stockholders.
• Future sales of the company's common stock in the public market could cause the market price of the common stock to decline.
• The company may face possible delisting if it fails to comply with the continued listing requirements of Nasdaq.
• The company is subject to risks not foreseen or fully appreciated by management.

Future Outlook

The company intends to use the net proceeds from the warrant exercise, if any, for general corporate purposes, including working capital.

Industry Context

The UV disinfection market is expected to reach $9 billion by 2027, driven by technology improvements and increased focus on stopping the spread of contagious diseases.

Comparison to Industry Standards

• The document mentions that Sterilumen's product portfolio is one of the only research-backed, clinically proven pure-play air and surface disinfection technology companies with international distribution and globally recognized end users, with product developed for NASA.
• The document mentions that Sterilumens air purification (Airocide, Scientific Air & PURO Lighting) and surface disinfection (Lumicide) were independently tested and proven to kill both Candida Auris (Resinnova Laboratories) and SARS CoV-2 (COVID-19) (MRIGlobal), MRSA (Resinnova Laboratories), Salmonella enterica (Resinnova Laboratories) and Escherichia coli (Resinnova Laboratories).

Stakeholder Impact

• Existing stockholders may experience dilution if the warrants are exercised.
• The offering and resale of common stock may affect the market price of the company's shares.
• The company's ability to raise capital in the future may be affected by the offering and resale of common stock.

Next Steps

• The selling stockholders may offer and sell their shares of common stock from time to time.
• The company intends to use the net proceeds from the exercise of warrants, if any, for general corporate purposes, including working capital.

Key Dates

Keywords

common stock, warrants, resale, offering, Applied UV, AUVI, selling stockholders, private placement, registration statement, dilution